Table 4.

Comparing 30-Day Costs in Patients with Adverse Events Receiving Immunotherapy or Targeted Therapy

Adverse event category	Overall patients, N	Immunotherapy cohort				Targeted therapy cohort				P valuea
		Patients, N	Patients with adverse event, %	Mean cost, $	SD, $	Patients, N	Patients with adverse event, %	Mean cost, $	SD, $
Cardiovascular	510	295	58	18,023	27,145	215	42	26,208	32,468	.05
Skin/subcutaneous tissue	447	249	56	21,535	32,648	198	44	21,967	33,464	.23
Other	394	134	34	17,176	27,118	260	66	17,774	28,064	<.01
Pain	383	197	52	24,152	34,404	186	48	21,997	33,501	<.01
Metabolic/nutritional	377	181	48	22,034	32,690	196	52	21,938	33,404	.05
Gastrointestinal	359	282	79	21,887	30,302	77	21	12,617	20,580	<.01
Hematologic/lymphatic	296	211	71	21,041	32,881	85	29	19,366	28,974	.32
Respiratory	295	223	76	31,179	38,703	72	24	28,525	35,650	<.01
CNS/psychiatric	261	127	49	27,979	39,041	134	51	26,334	32,625	.15
General disorder/administration-site condition	199	48	24	23,431	33,137	151	76	29,192	36,564	.02

^aThe Kruskal-Wallis test was used to assess the between-group differences in adverse event costs, with P value <5% considered statistically significant.

CNS indicates central nervous system; SD, standard deviation.